Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 44

Related Articles by Review for PubMed (Select 17697139)

1.

Influence of CYP2C19 and CYP3A4 gene polymorphisms on clopidogrel responsiveness in healthy subjects.

Fontana P, Hulot JS, De Moerloose P, Gaussem P.

J Thromb Haemost. 2007 Oct;5(10):2153-5. Epub 2007 Aug 3. No abstract available.

PMID:
17697139
2.

Genetic causes of clopidogrel nonresponsiveness: which ones really count?

Momary KM, Dorsch MP, Bates ER.

Pharmacotherapy. 2010 Mar;30(3):265-74. doi: 10.1592/phco.30.3.265. Review.

PMID:
20180610
3.

Factors associated with clopidogrel nonresponsiveness.

Momary KM, Dorsch MP.

Future Cardiol. 2010 Mar;6(2):195-210. doi: 10.2217/fca.10.1. Review.

PMID:
20230261
4.

Clopidogrel resistance: pharmacokinetic or pharmacogenetic?

Ford NF.

J Clin Pharmacol. 2009 May;49(5):506-12. doi: 10.1177/0091270009332433. Epub 2009 Feb 26. Review.

PMID:
19246723
5.

The genetic basis of platelet responsiveness to clopidogrel. A critical review of the literature.

Fefer P, Matetzky S.

Thromb Haemost. 2011 Aug;106(2):203-10. doi: 10.1160/TH11-04-0228. Epub 2011 Jul 12. Review.

PMID:
21792462
6.

Clopidogrel pharmacogenetics and its clinical implications.

Singh M, Thapa B, Arora R.

Am J Ther. 2010 May-Jun;17(3):e66-73. doi: 10.1097/MJT.0b013e3181afbf62. Review.

PMID:
19636246
7.

Individual and ethnic differences in CYP2C19 activity in Chinese populations.

Shu Y, Zhou HH.

Acta Pharmacol Sin. 2000 Mar;21(3):193-9. Review. No abstract available.

8.

Effects of genetic polymorphism of cytochrome P450 enzymes on the pharmacokinetics of benzodiazepines.

Fukasawa T, Suzuki A, Otani K.

J Clin Pharm Ther. 2007 Aug;32(4):333-41. Review.

PMID:
17635335
9.

Implementing genotype-guided antithrombotic therapy.

Seip RL, Duconge J, Ruaño G.

Future Cardiol. 2010 May;6(3):409-24. doi: 10.2217/fca.10.6. Review.

10.

Genetic variability in response to clopidogrel therapy and its clinical implications.

Yukhanyan L, Freynhofer MK, Siller-Matula J, Schrör K, Huber K.

Thromb Haemost. 2011 May;105 Suppl 1:S55-9. doi: 10.1160/THS10-11-0747. Epub 2011 Apr 11. Review.

PMID:
21479337
11.

[Genetic polymorphism of drug metabolizing enzymes].

Yokoi T, Kamataki T.

Seikagaku. 1997 Oct;69(10):1196-9. Review. Japanese. No abstract available.

PMID:
9431010
12.

Genetic polymorphism of cytochrome P450 and methods for its determination.

Buzková H, Pechandová K, Slanar O, Perlík F.

Prague Med Rep. 2006;107(4):383-93. Review.

PMID:
17402551
13.

Progress of antiplatelet pharmacogenomics.

Oestreich JH.

Curr Drug Targets. 2011 Nov;12(12):1848-58. Review.

PMID:
21718233
14.

Ethnic differences in genetic polymorphisms of CYP2D6, CYP2C19, CYP3As and MDR1/ABCB1.

Ozawa S, Soyama A, Saeki M, Fukushima-Uesaka H, Itoda M, Koyano S, Sai K, Ohno Y, Saito Y, Sawada J.

Drug Metab Pharmacokinet. 2004 Apr;19(2):83-95. Review.

15.

Testing for cytochrome P450 polymorphisms in adults with non-psychotic depression treated with selective serotonin reuptake inhibitors (SSRIs).

Matchar DB, Thakur ME, Grossman I, McCrory DC, Orlando LA, Steffens DC, Goldstein DB, Cline KE, Gray RN.

Evid Rep Technol Assess (Full Rep). 2007 Jan;(146):1-77. Review.

16.

Bedside evaluation of thienopyridine antiplatelet therapy.

Price MJ.

Circulation. 2009 May 19;119(19):2625-32. doi: 10.1161/CIRCULATIONAHA.107.696732. Review. No abstract available.

17.

[The role of CYP2C19 polymorphism in the development of adverse effects to drugs and the risk for diseases].

Alonso-Navarro H, Jiménez-Jiménez FJ, García-Agúndez JA.

Med Clin (Barc). 2006 May 13;126(18):697-706. Review. Spanish.

PMID:
16759580
18.

[Progress in the studies on the CYP2C19 polymorphism].

He N, Zhou HH.

Sheng Li Ke Xue Jin Zhan. 2003 Apr;34(2):171-4. Review. Chinese. No abstract available.

PMID:
12889158
19.

[Advances in the study of pharmacogenetics in China in 1996].

Xie H, Zhou H.

Zhonghua Yi Xue Za Zhi. 1997 Jan;77(1):77-8. Review. Chinese. No abstract available.

PMID:
9596985
20.

[A current problem for regulators. Clopidogrel and pharmacokinetics].

Zündorf I, Dingermann T.

Pharm Unserer Zeit. 2009;38(4):360-7. doi: 10.1002/pauz.200900326. Review. German. No abstract available.

PMID:
19572363
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk